MedTrace Logo

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)

NCT02806102 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 13000

Last updated 2016-07-06

No results posted yet for this study

Summary

This study is intended to provide contemporary data on the residual cardiovascular risk in all consecutive patients with acute myocardial infarction, especially in patients who survived stably within one-year after percutaneous coronary intervention.

In addition, this study will identify which baseline clinical, angiographic, or treatment factors are associated with residual cardiovascular risk and bleeding events

Conditions

Interventions

PROCEDURE

Percutaneous coronary intervention

Percutaneous coronary intervention

DRUG

Dual-antiplatelet therapy

Dual AntiPlatelet Therapy

PROCEDURE

Percutaneous coronary intervention

Percutaneous coronary intervention

DRUG

Dual-antiplatelet therapy

Dual AntiPlatelet Therapy

Sponsors & Collaborators

  • The Catholic University of Korea

    collaborator OTHER

  • Chonnam National University

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Kiyuk Chang, MD, PhD · Seoul St. Mary's Hospital

  • Youngkeun Ahn, MD, PhD · Chonnam National University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2017-02-28
Completion
2018-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02806102 on ClinicalTrials.gov